Executive Summary
CMS is weighing a new National Coverage Determination for TAVR that could reshape US access, arriving the same week Medtronic recalled a heart valve delivery system for safety reasons and the FTC fined Edwards $10M over its JC Medical deal. A pathophysiology-first reframing of tricuspid regurgitation in European Journal of Heart Failure argues that TR severity alone should not drive interventional decisions — a caution that lands as transcatheter TR volumes accelerate under ESC 2025's new Class IIa endorsement. A TriNetX cohort of severe AS with cardiogenic shock found no MACE difference between direct TAVR and staged BAV-TAVR at 3 years (HR 1.17, 95% CI 0.89–1.53), complicating the case for routine bridging without settling it.
- The proposed 2026 TAVR NCD could rewrite volume requirements and heart-team rules, per Mack and Badhwar on Rox Heart Radio.
- Medtronic pulled a heart valve delivery system over safety risk, a fresh headwind after a 15% six-month stock decline (Cardiovascular Business).
- Jenscare hit a global enrollment milestone for the LuX-Valve Plus TTVR trial, expanding the tricuspid replacement field beyond EVOQUE.
- NCDR analysis on BMI × age interaction in TAVR outcomes refines the obesity-paradox debate at 1 year.
- An editorial in Journal of Geriatric Cardiology urges caution on bicuspid TAVR — echoing the ESC 2025 Class IIb designation for BAV.
What to watch: Abbott reports earnings tomorrow (July 16), with structural heart franchise commentary on TriClip and MitraClip against the ESC 2025 Class I upgrade for TEER in ventricular SMR.
Aortic Valve (TAVR/TAVI)
Regulatory and access questions eclipsed clinical data today. The CMS proposed National Coverage Determination for TAVR, discussed by Mack and Badhwar on Rox Heart Radio, could revise volume thresholds, heart-team composition, and shared decision-making requirements — the scaffolding erected in the 2019 NCD when TAVR expanded to low-risk. Badhwar's involvement signals that surgical concerns about further indication creep will be central to the negotiation. A National Taxpayers Union brief argues expanded Medicare TAVR access reduces costs — the political tailwind for broader coverage.
The TriNetX study of 396 propensity-matched patients with severe AS and cardiogenic shock found no MACE difference between direct TAVR and staged BAV-TAVR at 30 days, 1 year, or 3 years. The authors correctly flag survivor bias — patients who died before TAVR could be performed were excluded — and label the results hypothesis-generating, not equivalence. ACC/AHA 2020 leaves shock management to Heart Team judgment; this data does not change that. An editorial in Journal of Geriatric Cardiology flagged the evidence gap for bicuspid TAVR, aligned with the ESC 2025 Class IIb rating and SAVR preference for younger BAV patients with aortopathy — a reminder that the BAV population remains poorly represented in TAVI RCTs, with NOTION 2 showing a numerically higher event rate favoring SAVR (HR 3.8, P=0.07). A JACC Case Reports case of bioprosthetic valve fracture during ViV-TAVR in a small Braile bioprosthesis underscores that lifetime management planning at the index SAVR matters — a point ESC 2025 elevated to formal guidance.
Mitral Valve (MitraClip, PASCAL, TMVR)
No mitral RCTs today. The field holds with ESC 2025's Class I upgrade of TEER for ventricular secondary MR — still Class IIa under ACC/AHA 2020 — a gap that will define the next ACC/AHA revision cycle. A Frontiers in Medical Technology case report documented a large persistent iatrogenic ASD after bioprosthetic MVR combined with tricuspid annuloplasty, ultimately closed with a dual-device transcatheter strategy. Transseptal complications from left-atrial access are a real and underreported cost of the transcatheter era.
Tricuspid Valve (TriClip, TTVR)
A European Journal of Heart Failure review by Kresoja, Stolz, and colleagues argues TR management should be reframed around pathophysiology and comorbidities — hemodynamic assessment, portal vein Doppler, liver stiffness — rather than TR grade in isolation. [NOTABLE] The argument carries weight because TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — the trials underpinning ESC 2025's Class IIa endorsement of transcatheter TR therapy — demonstrated QoL and HF hospitalization benefits but not mortality reduction. If TR is downstream of HF rather than driving it, the intervention's ceiling is lower than current volumes imply. ACC/AHA 2020 carries no transcatheter TR recommendation; this review supplies direct ammunition for measured US uptake. For surgical context: ESC 2025 upgraded TV surgery for symptomatic primary TR to Class I precisely because too-late referral has historically produced the worst surgical outcomes — the same patient-selection discipline Kresoja applies to transcatheter candidates.
On the device side, Jenscare announced a milestone in its global trial for the LuX-Valve Plus TTVR system, extending the transcatheter TVR field beyond Edwards' EVOQUE. A JACC Case Reports workflow paper described echocardiographer-led combined transjugular ICE + TEE guidance for tricuspid TEER — a signal that procedural imaging complexity remains a rate limiter on adoption.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. The Kresoja EJHF review widens the gap between transcatheter TR enthusiasm and surgical caution: patient selection is the variable that determines outcomes in both domains. ESC 2025's Class I upgrade for surgical TV repair in symptomatic primary TR and Class IIa for transcatheter TR therapy in high-risk patients are parallel tracks, not competing ones — the pathophysiology framework argues both fail when applied without the discipline to identify who is genuinely TR-driven versus HF-driven.
Device & Technology
Medtronic recalled a heart valve delivery system over safety risk, per Cardiovascular Business — a fresh operational headwind atop MDT's structural heart franchise pressures. A Baylor case report on snare-assisted bailout of an embolized Evolut FX using a cross-platform SAPIEN 3 Ultra "valve-through-valve" implant illustrates a real-world workaround; registry embolization rates remain the more useful signal for operators than isolated case reports. A Journal of Clinical Medicine review flagged polymeric heart valves as the next frontier for THV durability — still preclinical, but directly relevant to the durability debate ESC 2025 sidestepped by citing "comparable" SVD rates to 10 years without acknowledging the survival bias and variable SVD definitions that limit those comparisons.
Regulatory & Policy
The proposed CMS NCD for TAVR is the story to watch through year-end. Any loosening of volume thresholds or heart-team composition rules would accelerate community-hospital TAVR uptake — the scenario surgical leadership has consistently flagged as a risk for outcomes drift. Separately, the FTC fined Edwards $10M over the JC Medical acquisition, with the total settlement reaching $12M inclusive of Genesis MedTech per Medical Buyer — a reminder that consolidation in the TAVR space now draws antitrust scrutiny.
Industry & Market
Edwards underperformed peers Wednesday, closing at $87.27 (-3.13%) ahead of July 23 earnings. Analyst targets diverge: Mizuho raised its target to $105, Baird lifted to $94 but stayed Neutral. The FTC settlement and CMS NCD uncertainty are near-term overhangs; the durability question remains the long-term one.
Financial Analysis
The valve-industry tape reflects regulatory risk pricing in real time. Edwards' 3% Wednesday drop coincides with FTC settlement headlines and pre-earnings positioning; Medtronic's device recall lands with the stock down 15% over six months, well below the peer group. Boston Scientific's -51% six-month move continues to reflect the January guidance reset, not a valve-specific event. Abbott's positive-territory print into July 16 earnings assumes structural heart (MitraClip, TriClip, Navitor) delivers — the ESC 2025 Class I upgrade for TEER in ventricular SMR is a real tailwind for MitraClip volumes globally. The market signal to watch: whether the CMS NCD proposal is read as expanding or restricting TAVR access. Edwards and Medtronic sit on opposite sides of that outcome depending on volume-threshold language.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $87.27, -3.13% Wednesday, +3.46% over 6 months
- Market cap $50.3B; trailing P/E 48.75, forward P/E 25.96; beta 0.85; 52-week range $72.30–$96.29
- Analyst consensus: Buy, target $98.58 (26 analysts, range $84–$110)
- Next earnings: July 23 (EPS est $0.74, Rev est $1.70B)
- Commentary: FTC $10M settlement over JC Medical, plus Mizuho ($105) vs Baird ($94) target divergence, define the noise. Wednesday underperformance reflects pre-earnings positioning and the CMS NCD overhang.
Medtronic (MDT)
- Close: $80.47, +1.48% Wednesday, -15.40% over 6 months
- Market cap $103.0B; trailing P/E 21.29, forward P/E 12.57; beta 0.58; 52-week range $73.31–$106.33
- Analyst consensus: Buy, target $97.84 (25 analysts)
- Next earnings: August 18 (EPS est $1.39, Rev est $9.55B)
- Commentary: Heart valve delivery system recall adds to an already tough six months. Evolut FX embolization case reports don't help sentiment.
Abbott (ABT)
- Close: $89.27, +1.06% Wednesday
- Market cap $155.5B; trailing P/E 25.01, forward P/E 14.74; beta 0.61; 52-week range $81.97–$137.49
- Analyst consensus: Buy, target $116.54 (24 analysts)
- Next earnings: July 16 (EPS est $1.28, Rev est $12.52B)
- Commentary: Earnings tomorrow. Structural heart commentary on TriClip and MitraClip is the key line, especially with ESC 2025's Class I TEER upgrade providing a global tailwind.
Boston Scientific (BSX)
- Close: $43.04, +0.96% Wednesday, -51.13% over 6 months
- Market cap $64.0B; trailing P/E 17.86, forward P/E 11.6; beta 0.58; 52-week range $42.20–$109.50
- Analyst consensus: Strong Buy, target $72.50 (28 analysts)
- Next earnings: July 29 (EPS est $0.83, Rev est $5.37B)
- Commentary: Sitting at 52-week lows. ACURATE neo2 remains the structural heart story to watch.
Anteris Technologies (AVR.AX)
- Close: A$12.49, -0.64% Wednesday, +80.49% over 6 months
- Market cap $1.2B; forward P/E -5.73; beta 0.73; 52-week range $4.68–$15.47
- Commentary: DurAVR THV pipeline story continues to drive outsized returns despite small revenue base.
Market outlook: The valve-industry tape splits into two stories — the incumbents (EW, MDT) navigating regulatory and durability questions, and the challengers (BSX, AVR.AX) trading on device-specific narratives. The CMS NCD decision is the single biggest binary event on the horizon.
Clinical Trial Updates
Aortic:
- NCT07705425 — EPX-HTG for Structural Heart Procedures (EchoPixel). Not yet recruiting. Phase N/A. N=20. Covers LAAO and mitral TEER imaging support.
Withdrawn / Terminated:
- NCT07202104 — Eko digital stethoscope algorithm for structural heart murmur detection. Withdrawn.
- NCT03152773 — MRI fluoroscopy heart catheterization (NHLBI). Terminated, N=22.
The landmark trial roster — REPAIR-MR, PRIMARY, TRILUMINATE, CLASP TR, APOLLO, TRISCEND II, PARTNER, COAPT, EARLY TAVR — continues to define the guideline evidence base. No status changes on those today.
Forward look: Abbott earnings tomorrow, Edwards on July 23, and the CMS NCD proposal timeline will define valve-industry sentiment through Q3. The Kresoja EJHF framework will echo in the tricuspid intervention debate long after the news cycle moves on.